Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
3.680
+0.070 (1.94%)
Aug 28, 2026, 12:15 PM EDT - Market open
Genprex Employees
Genprex had 13 employees as of December 31, 2025. The number of employees decreased by 3 or -18.75% compared to the previous year.
Employees
13
Change
-3
Growth
-18.75%
Revenue / Employee
n/a
Profits / Employee
-$1,269,120
Market Cap
3.02M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 13 | -3 | -18.75% | 13 | 0 |
| Sep 30, 2025 | 13 | -6 | -31.58% | 13 | 0 |
| Jun 30, 2025 | 15 | -6 | -28.57% | 15 | 0 |
| Mar 31, 2025 | 15 | -11 | -42.31% | 15 | 0 |
| Dec 31, 2024 | 16 | -10 | -38.46% | 16 | 0 |
| Sep 30, 2024 | 19 | -12 | -38.71% | 19 | 0 |
| Jun 30, 2024 | 21 | -9 | -30.00% | 21 | 0 |
| Dec 31, 2023 | 26 | -2 | -7.14% | 26 | 0 |
| Sep 30, 2023 | 31 | 9 | 40.91% | 31 | 0 |
| Jun 30, 2023 | 30 | 8 | 36.36% | 30 | 0 |
| Mar 31, 2023 | 28 | 9 | 47.37% | 28 | 0 |
| Dec 31, 2022 | 28 | 11 | 64.71% | 28 | 0 |
| Sep 30, 2022 | 22 | 6 | 37.50% | 22 | 0 |
| Jun 30, 2022 | 22 | 6 | 37.50% | 22 | 0 |
| Mar 31, 2022 | 19 | 7 | 58.33% | 19 | 0 |
| Dec 31, 2021 | 17 | 5 | 41.67% | 17 | 0 |
| Sep 30, 2021 | 16 | 4 | 33.33% | 16 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Calidi Biotherapeutics | 29 |
| Curis | 24 |
| Revelation Biosciences | 9 |
| Artelo Biosciences | 7 |
| Galmed Pharmaceuticals | 6 |
| Jupiter Neurosciences | 5 |
| 60 Degrees Pharmaceuticals | 3 |
GNPX News
- 10 days ago - Genprex selects manufacturing organization for diabetes gene therapy - TheFly
- 10 days ago - Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy - PRNewsWire
- 25 days ago - Genprex announces collaboration with Roche Diagnostics - TheFly
- 25 days ago - Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies - PRNewsWire
- 6 weeks ago - Genprex trading halted, news pending - TheFly
- 2 months ago - Genprex says CIPO issues Notice of Allowance for patent - TheFly
- 2 months ago - Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer - PRNewsWire
- 2 months ago - Genprex to Participate at BIO International Convention 2026 - PRNewsWire